Proto Script Pharmaceutical (Proto Script Pharmaceutical) EV-to-EBIT : 0.00 (As of May. 25, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Proto Script Pharmaceutical EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Proto Script Pharmaceutical's Enterprise Value is $0.00 Mil. Proto Script Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Sep. 2017 was $-0.85 Mil. Therefore, Proto Script Pharmaceutical's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Proto Script Pharmaceutical's EV-to-EBIT or its related term are showing as below:

PSCR's EV-to-EBIT is not ranked ^*
in the Business Services industry.
Industry Median: 12.53
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Proto Script Pharmaceutical's Enterprise Value for the quarter that ended in Sep. 2017 was $2.34 Mil. Proto Script Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Sep. 2017 was $-0.85 Mil. Proto Script Pharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2017 was -36.49%.

Proto Script Pharmaceutical EV-to-EBIT Historical Data

The historical data trend for Proto Script Pharmaceutical's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proto Script Pharmaceutical EV-to-EBIT Chart

Proto Script Pharmaceutical Annual Data

Trend

May12

May13

May14

May15

May16

EV-to-EBIT

-278.97

-284.93

-254.99

-201.02

-17.58

Proto Script Pharmaceutical Quarterly Data
	Nov12	Feb13	May13	Aug13	Nov13	Feb14	May14	Aug14	Nov14	Feb15	May15	Aug15	Nov15	Feb16	May16	Sep16	Dec16	Mar17	Jun17	Sep17
EV-to-EBIT	Get a 7-Day Free Trial															-985.22	-655.48	-5.47	-3.21	-2.74

Competitive Comparison of Proto Script Pharmaceutical's EV-to-EBIT

For the Specialty Business Services subindustry, Proto Script Pharmaceutical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Proto Script Pharmaceutical's EV-to-EBIT Distribution in the Business Services Industry

For the Business Services industry and Industrials sector, Proto Script Pharmaceutical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Proto Script Pharmaceutical's EV-to-EBIT falls into.

Proto Script Pharmaceutical EV-to-EBIT Calculation

Proto Script Pharmaceutical's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/	-0.854
	=	0.00

Proto Script Pharmaceutical's current Enterprise Value is $0.00 Mil.
Proto Script Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.85 Mil.

Proto Script Pharmaceutical (OTCPK:PSCR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Proto Script Pharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2017 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2017 )	=	EBIT	/	Enterprise Value (Q: Sep. 2017 )
	=	-0.854	/	2.3406
	=	-36.49 %

Proto Script Pharmaceutical's Enterprise Value for the quarter that ended in Sep. 2017 was $2.34 Mil.
Proto Script Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.85 Mil.

Proto Script Pharmaceutical EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Proto Script Pharmaceutical's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Proto Script Pharmaceutical (Proto Script Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Business Services » Proto Script Pharmaceutical Corp (OTCPK:PSCR) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

9830 6th Street, Suite 103, Rancho Cucamonga, CA, USA, 91730

Website

http://www.psphomecare.com

Proto Script Pharmaceutical Corp is primarily in the business of repair power wheelchairs and scooters, which are classified as durable medical equipment (DME) products and reimbursable by healthcare insurance providers. It has various contracts with state and governmental insurance providers, among others. These contracts provide the company with the right to sell and repair DME and its health care insurance contracts allow it the ability to service patients nationally. The group currently has its presence of repair facilities in Las Vegas, Nevada, Rancho-Cucamonga, and Anaheim, California.

Proto Script Pharmaceutical (Proto Script Pharmaceutical) Headlines

No Headlines